Celltrion Healthcare showcases inflammatory bowel disease solutions

[Courtesy of Celltrion Healthcare]

South Korean biopharmaceutical company Celltrion Healthcare Co. presented the Celltrion Group’s inflammatory bowel disease (IBD) treatment to leading global healthcare professionals during its Global IBD Homecoming Day 2023, which kicked off on Tuesday.

The biopharmaceutical company invites key stakeholders from around the world to Korea for the event it organizes to promote its products as well as share the latest medical trends and prescription cases domestically and internationally. Around 40 IBD specialists from 11 countries participated in this year’s event.

At a marketing session on the first day of the event, the company presented the features and real-world data of some of the company’s latest developments, including Remsima SC, which has recently been approved in the United States (as Zymfentra), and Yuflyma (adalimumab). Participants particularly noted the competitiveness of Remsima SC during the subsequent medical sessions, where discussions focused on the efficacy and safety data for both increased and monotherapy doses, as confirmed in the global phase 3 post-analysis.

On the second day of the event, participants met with domestic healthcare professionals at Asan Medical Center’s gastroenterology department. Researchers and attendees exchanged opinions on IBD-related treatment trends on a multinational scale, and shared experiences from actual medical settings, including patient cases.

The Global IBD Homecoming Day event will continue until Saturday.